Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,539 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study.
Nakamura N, Arima N, Takakuwa T, Yoshioka S, Imada K, Fukushima K, Hotta M, Fuchida SI, Kanda J, Uoshima N, Shimura Y, Tanaka H, Ohta K, Kosugi S, Yagi H, Yoshihara S, Yamamura R, Adachi Y, Hanamoto H, Shibayama H, Hosen N, Ito T, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Hino M; Kansai Myeloma Forum. Nakamura N, et al. Among authors: fukushima k. Ann Hematol. 2024 Mar 16. doi: 10.1007/s00277-024-05705-z. Online ahead of print. Ann Hematol. 2024. PMID: 38492020
AML1/RUNX1 works as a negative regulator of c-Mpl in hematopoietic stem cells.
Satoh Y, Matsumura I, Tanaka H, Ezoe S, Fukushima K, Tokunaga M, Yasumi M, Shibayama H, Mizuki M, Era T, Okuda T, Kanakura Y. Satoh Y, et al. Among authors: fukushima k. J Biol Chem. 2008 Oct 31;283(44):30045-56. doi: 10.1074/jbc.M804768200. Epub 2008 Aug 7. J Biol Chem. 2008. PMID: 18687690 Free PMC article.
Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine.
Maeda T, Hosen N, Fukushima K, Tsuboi A, Morimoto S, Matsui T, Sata H, Fujita J, Hasegawa K, Nishida S, Nakata J, Nakae Y, Takashima S, Nakajima H, Fujiki F, Tatsumi N, Kondo T, Hino M, Oji Y, Oka Y, Kanakura Y, Kumanogoh A, Sugiyama H. Maeda T, et al. Among authors: fukushima k. Blood Cancer J. 2013 Aug 2;3(8):e130. doi: 10.1038/bcj.2013.29. Blood Cancer J. 2013. PMID: 23912610 Free PMC article. No abstract available.
Quantitative polymerase chain reaction analysis with allele-specific oligonucleotide primers for individual IgH VDJ regions to evaluate tumor burden in myeloma patients.
Sata H, Shibayama H, Maeda I, Habuchi Y, Nakatani E, Fukushima K, Fujita J, Ezoe S, Tadokoro S, Maeda T, Mizuki M, Kosugi S, Nakagawa M, Ueda S, Iida M, Tokumine Y, Azenishi Y, Mitsui H, Oritani K, Kanakura Y. Sata H, et al. Among authors: fukushima k. Exp Hematol. 2015 May;43(5):374-381.e2. doi: 10.1016/j.exphem.2015.01.002. Epub 2015 Jan 13. Exp Hematol. 2015. PMID: 25591497 Free article.
Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation.
Ueda T, Maeda T, Kusakabe S, Fujita J, Fukushima K, Yokota T, Shibayama H, Tomiyama Y, Kanakura Y. Ueda T, et al. Among authors: fukushima k. Int J Hematol. 2019 Feb;109(2):197-205. doi: 10.1007/s12185-018-2562-8. Epub 2018 Nov 17. Int J Hematol. 2019. PMID: 30448938
Influence of HLA 1-3-locus mismatch and antithymocyte globulin administration in unrelated bone marrow transplantation.
Kawamura K, Kanda J, Ohashi K, Fukuda T, Iwato K, Eto T, Fujiwara SI, Mori T, Fukushima K, Ozawa Y, Uchida N, Ashida T, Ichinohe T, Atsuta Y, Kanda Y. Kawamura K, et al. Among authors: fukushima k. Ann Hematol. 2020 May;99(5):1099-1110. doi: 10.1007/s00277-020-03995-7. Epub 2020 Mar 23. Ann Hematol. 2020. PMID: 32206853 Clinical Trial.
2,539 results